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ABSTRACT 32 
Objective: Hyperandrogenism in congenital adrenal hyperplasia (CAH) 33 
provides an in vivo model for exploring the effect of androgens on 34 
erythropoiesis in women. We investigated the association of androgens with 35 
haemoglobin (Hb) and haematocrit (Hct) in women with CAH. 36 
Design: Cross-validation study 37 
Patients: Women with CAH from Sheffield Teaching Hospitals, UK (cohort 1, 38 
the training set: n=23) and National Institutes of Health, USA (cohort 2, the 39 
validation set: n=53). 40 
Measurements: Androgens, full blood count and basic biochemistry, all 41 
measured on the same day. Demographic and anthropometric data. 42 
Results: Significant age-adjusted correlations (P<0.001) were observed for 43 
Ln testosterone with Hb and Hct in cohorts 1 and 2 (Hb r=0.712 & 0.524 and 44 
Hct r=0.705& 0.466), and remained significant after adjustments for CAH 45 
status, glucocorticoid treatment dose and serum creatinine. In the combined 46 
cohorts Hb correlated with androstenedione (P=0.002) and 17-47 
hydroxyprogesterone (P=0.008). Hb and Hct were significantly higher in 48 
cohort 1 than those in cohort 2, while there were no group differences in 49 
androgen levels, glucocorticoid treatment dose or body mass index. In both 50 
cohorts women with Hb and Hct in the highest tertile had significantly higher 51 
testosterone levels than women with Hb and Hct in the lowest tertile.  52 
Conclusions: In women with CAH, erythropoiesis may be driven by 53 
androgens and could be considered a biomarker for disease control.  54 
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INTRODUCTION 55 
The effect of androgens on erythropoiesis is well described and initially came 56 
to light through the observation that men have higher levels of haemoglobin 57 
(Hb) than women 1. Pre-pubertal boys and girls have similar levels of Hb but 58 
boys acquire higher Hb levels following puberty that coincides with the surge 59 
in testosterone levels 2. Lower Hb levels in women are not due to chronic 60 
menstrual blood loss as this gender difference persists in non-menstruating 61 
women 3, 4. The evidence for an erythropoietic effect of testosterone led to its 62 
use as a treatment for anaemia in renal failure 4 and bone marrow failure 5 in 63 
the past before the invent of recombinant erythropoietin. In men intramuscular 64 
testosterone replacement, is often associated with polycythemia 6, which 65 
reverses with a dose reduction or discontinuation of therapy 7. Conversely, 66 
androgen deprivation therapy for prostate cancer leads to a reduction in Hb 67 
levels 8.  68 
 69 
Congenital adrenal hyperplasia (CAH) is the commonest genetic endocrine 70 
disorder and 21-hydroxylase deficiency accounts for more than 95% of the 71 
cases 9. In this condition, defective cortisol synthesis in the adrenal glands 72 
leads to the loss of negative feedback inhibition of ACTH secretion by the 73 
pituitary. The elevated ACTH leads to hyperplasia of the adrenal glands and 74 
excess production of adrenal androgens 9. Treatment with glucocorticoids 75 
aims to control the androgen excess and replace the steroid deficiencies; 76 
however it is challenging to achieve the correct balance between over and 77 
under-treatment. When patients are under-replaced, adrenal androgens are 78 
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elevated and women are affected by symptoms of hyperandrogenism. With 79 
over-replacement adrenal androgens are suppressed.  80 
 81 
The effect of elevated adrenal androgens on erythropoietic markers in 82 
patients with CAH has been assumed but not studied in detail. Polycythaemia 83 
is seen in neonates with CAH 10 and there have been a few case studies 84 
reporting polycythemia in untreated men and women with CAH and androgen 85 
excess 11, 12. To the best of our knowledge, there are no studies examining the 86 
relationship of androgens and erythropoiesis in women with CAH. The present 87 
study investigates the association of androgens with Hb and haematocrit (Hct) 88 
in women with CAH in a cross-validated study. 89 
 90 
METHODS 91 
Study population 92 
This was a retrospective analysis of data from two cohorts of CAH patients 93 
managed in two tertiary centers with expertise on the management of CAH. 94 
Cohort 1 comprised of patients from Sheffield Teaching Hospitals, UK and 95 
cohort 2 from National Institutes of Health, Bethesda, USA.  96 
 97 
Data gathering  98 
Demographic, anthropometric, biochemical, haematological and hormonal 99 
data measured on the same day were recorded. A total of 83 women (cohort 100 
1: n = 30, cohort 2: n = 53) with CAH were eligible for recruitment. Seven 101 
women were excluded from cohort 1 prior to the analysis (four due to 102 
incomplete biochemical data and three due to medical conditions or 103 
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medications known to affect the erythropoiesis or red cell parameters i.e. iron 104 
deficiency anaemia, vitamin B12 deficiency and methotrexate treatment). After 105 
screening for completeness, data of 76 women were used in the final 106 
analysis, 23 in cohort 1 and 53 in cohort 2. 107 
 108 
Biochemical data for androgens [total testosterone, androstenedione and 17-109 
hydroxyprogesterone (17-OHP)], full blood count, serum urea, creatinine and 110 
electrolytes were retrieved from electronic data systems. In cohort 1 the 111 
majority of samples were measured between 0800-1400hrs during clinic 112 
visits, after the morning dose of glucocorticoids, whereas for cohort 2 most 113 
samples were measured before the morning dose of glucocorticoids between 114 
0700-0900hrs. The two laboratories had different reference ranges for Hb 115 
(cohort 1 110-147g/L, cohort 2 112g/L-157g/L). Hence, the tertiles were used 116 
for comparison between two cohorts in analysis. Age, height, weight, 117 
glucocorticoid treatment dose, CAH phenotype and smoking, medical and 118 
drug history were obtained from medical case notes. Body mass index (BMI) 119 
was calculated; weight (kg) divided by height (m) squared (kg/m2). Since 120 
patients were treated with different glucocorticoid regimens (hydrocortisone, 121 
prednisolone/prednisone and dexamethasone), those glucocorticoid doses 122 
were converted to hydrocortisone equivalent dose using the ratio 123 
hydrocortisone: prednisolone: dexamethasone of 1:5:80 13. The values used 124 
to calculate the hydrocortisone equivalent doses vary widely and we chose to 125 
use 5 times potency for prednisolone/prednisone, which is the widely 126 
accepted. For dexamethasone we chose that originally proposed by Wilkins in 127 
1965 "The potency of this glucocorticoid in suppressing adrenal steroid 128 
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biosynthesis relative to cortisol is about 80ௗ´ and partially evaluated in CAH 129 
by Rivkees 13.  130 
 131 
Hormonal assays  132 
In cohort 1, 17-OHP was measured by the Siemens Coat-a-Count 133 
radioimmunoassay (RIA) [inter-assay coefficient of variance (CV) 5.0-11%] 134 
until October 2014 and thereafter with Diasource RIA (inter-assay CV 6.3-135 
16%). Androstenedione was measured using the Siemens Immulite 2000 136 
chemiluminescence immunoassay (CLIA) (inter-assay CV 8.5-12.0%) until 137 
February 2014 and using the Beckman Coulter Active RIA  (inter-assay CV 138 
4.5-16.9%) thereafter. Total Testosterone was measured using the Siemens 139 
Advia Centaur CLIA (inter-assay CV 6.8-13.3%) until January 2011 and by the 140 
Roche Cobas e602 electrochemiluminescence immunoassay (ECLIA) (inter-141 
assay CV 3.5-7.3%).  142 
 143 
In cohort 2 all the androgens were analyzed by liquid chromatography-tandem 144 
mass spectrometry (LC-MS/MS). From 2005 to 2012 assays were performed 145 
at Mayo Medical Laboratories, Rochester, MN; The androstenedione assay 146 
had a sensitivity of 15ng/dl; inter-assay CV of 7.9, 7.2, 8.7%; intra-assay CV 147 
of 13.9, 5.9, 2.6 at mean concentration of 112, 916, and 2281ng/dl 148 
respectively, and normal range of 40-150ng/dl for males and 30-200ng/dl for 149 
females. The 17-OHP assay had an analytical sensitivity of 40ng/dl, inter-150 
assay CV of 9.7, 8.7, 6.8%; intra-assay CV of 6.8, 2.9, 4.4% with a mean 151 
concentration of 111, 751, and 2006ng/dl, respectively, and normal range of 152 
less than or equal to 220ng/dl for males and less than or equal to 285ng/dl for 153 
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females; 2012 onwards androstenedione and 17-OHP were measured by LC-154 
MS/MS at National Institutes of Health, Bethesda MD; intra-assay CV ranged 155 
from 2.5-9.5% and inter-assay CV from 2.9 - 11.1%.  156 
 157 
Statistical analysis: 158 
Data were analyzed using SPSS v22. Group differences were determined by 159 
6WXGHQW¶VW-tests. Relationships of Hb and Hct with androgens were assessed 160 
by partial correlations to enable adjustments for confounding factors including 161 
age, study cohorts, glucocorticoid treatment dose, CAH status and renal 162 
function. Data for androgens and glucocorticoid treatment dose were 163 
logarithmically transformed due to being positively skewed.  164 
 165 
RESULTS 166 
Characteristics of the study populations 167 
Mean age of women in cohort 1 was 35.3 (SD ±14) years (Table 1). Among 168 
this cohort of women, 17 (73.9%) had classic CAH, in whom 13 (73%) were 169 
salt wasting and 4 (23%) simple virilizing subtypes, and 6 (26.1%) had non-170 
classic CAH. The mean age of women in cohort 2 was 30.8 (SD r11.4) years. 171 
This cohort comprised mostly of women with classic CAH (n = 51, 96.2%), of 172 
whom 33 (65%) had the salt wasting and 18 (35%) the simple virilizing type. 173 
There was one (1.9%) patient with non-classic CAH and one (1.9%) with 11-E 174 
hydroxylase deficiency.  175 
 176 
In cohort 1 the majority received either hydrocortisone alone (n=10, 43.47%) 177 
administered twice or thrice daily, or prednisolone alone (n=9, 39.1%) 178 
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administered once or twice daily. The remaining patients were treated with 179 
either dexamethasone once daily (n=2, 8.69%), or hydrocortisone and 180 
dexamethasone combined (n=2, 8.69%). In cohort 2, the majority was treated 181 
with prednisone (n=21, 39.6%) administered twice daily, followed by 182 
hydrocortisone (n=14, 26.4%) thrice daily, and dexamethasone once daily 183 
(n=12, 22.64%). Hydrocortisone combined with either prednisone or 184 
dexamethasone and prednisolone alone was given in one patient each 185 
(1.89%). 186 
 187 
Correlations of androgens with erythropoiesis 188 
The associations of testosterone with Hb and Hct in the two cohorts are 189 
shown in Figures 1 and 2. The regression slopes were similar in both cohorts 190 
but the intercepts were lower in cohort 2. In cohort 1, age adjusted Ln 191 
testosterone correlated positively with Hb and Hct (P <0.001) (Table 2). These 192 
relationships remained significant (P <0.01) after further adjustments for CAH 193 
status, glucocorticoid treatment dose and serum creatinine levels. The results 194 
from the cohort 2 confirmed these relationships but were less strong. These 195 
associations continued to persist after the two cohorts were analyzed together 196 
(Table 2). In both cohorts, the androgen precursors androstenedione and 17-197 
OHP also correlated with Hb and Hct but the correlations were weaker than 198 
for testosterone. 199 
 200 
Androgens, glucocorticoid treatment dose and anthropometry of women with 201 
erythropoietic markers in the highest tertile were compared with those of 202 
women in the lowest tertile (Table 3). Women with Hb or Hct in the highest 203 
tertile had significantly higher testosterone levels compared with women with 204 
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Hb or Hct in the lowest tertile in both cohorts. The same was true for 205 
androstenedione and 17-OHP in cohort 1 but only for androstenedione and 206 
Hb in cohort 2. In cohort 2 women in the highest tertile of Hb and Hct had a 207 
higher BMI and higher glucocorticoid treatment dose.  208 
 209 
Comparisons between cohort 1 and cohort 2  210 
There were no group differences in age, anthropometric, BMI or glucocorticoid 211 
treatment dose between cohorts 1 and 2 (Table 1). Women in cohort 1 had 212 
significantly higher mean Hb (P = 0.031) and Hct (P = 0.035) levels than those 213 
in cohort 2 (Table 1). Similarly, substantially higher proportions of women had 214 
Hb and Hct above the upper limit of the reference range in cohort 1 (Hb: 215 
30.4%, Hct: 47.8%) compared with cohort 2 (Hb, Hct <4%). The levels of total 216 
testosterone and its precursors, androstenedione and 17-OHP and creatinine 217 
levels did not differ significantly between the two study cohorts. 218 
 219 
DISCUSSION  220 
We have demonstrated that androgen levels in women with CAH are 221 
positively associated with Hb and Hct, suggesting that these markers of 222 
erythropoiesis are a potential biomarker of androgen control in women with 223 
CAH. The findings strengthen the evidence for an action of androgens on 224 
erythropoiesis in women. 225 
 226 
The mechanism by which androgens promote erythropoiesis is not 227 
established 1, 14. There are conflicting results on the effect of testosterone on 228 
erythropoietin, the major regulator of erythropoiesis. Some studies have 229 
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suggested that testosterone increases erythropoietin production 1, 15, while 230 
others found no evidence to support these findings 6, 16. Other possible 231 
mechanisms by which testosterone might induce erythropoiesis include a 232 
direct effect on the bone marrow hematopoietic stem cells by stimulating 233 
insulin-like growth factor 1 and erythrocyte colony forming units 17, and 234 
increasing intestinal iron absorption and incorporation into erythrocytes 14.  235 
 236 
Exogenous androgens have been associated with an increase in 237 
erythropoiesis. Supra-physiologic pharmaceutical doses of androgens cause 238 
an increase in Hb and Hct in men 18, which is dose-dependent and 239 
polycythaemia is a common but unwanted side-effect of testosterone therapy 240 
in hypogonadal men 6. Similarly in women, androgen therapy was associated 241 
with an increase in Hb and erythroid cell hyperplasia in bone marrow 242 
aspirates 19. In gender reassignment, hormone therapy raising testosterone 243 
levels in female-to-male reassignment leads to an increase in Hb levels while 244 
suppressed testosterone levels in male-to-female reassignment leads to a 245 
decrease in Hb levels 20. The levels of endogenous androgens has also been 246 
associated with erythropoiesis; healthy adult men with low free testosterone 247 
levels have a lower haematocrit than men with normal free testosterone 21 and 248 
Hb levels correlate with total and bioavailable testosterone in men and women 249 
older than 65 years 22. 250 
 251 
Conditions associated with significant hyperandrogenism VXFK DV &XVKLQJ¶V252 
disease and androgen producing ovarian tumors may present with 253 
polycythaemia 23, 24. We hypothesized that lower chronic elevations of 254 
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androgens may be associated with more subtle increases in erythropoietic 255 
markers. Women with CAH have elevated levels of adrenal androgens if 256 
inadequately treated with glucocorticoids 25 and provide a free-living model for 257 
exploring the effect of androgens on erythropoiesis. Cortisol has been 258 
implicated to play a mediating role in erythropoiesis 26, 27. Activation of the 259 
JOXFRFRUWLFRLG UHFHSWRU SURPRWHV µVWUHVV HU\WKURSRLHVLV¶ DQG PDWXUDWLRQ RI260 
erythroid progenitors in vitro 28. It is well documented that anaemia occurs in 261 
patients with hypocortisolism, e.g. SheeKDQ¶VV\QGURPH 29 and polycythemia 262 
in women with hypercortisolism 30. Correcting hypocortisolism with 263 
glucocorticoid replacement 31 or hypercortisolism by surgery 24 leads to 264 
normalization of Hb levels. Hypogonadal men with DFWLYH&XVKLQJ¶V disease 265 
have low erythroid parameters that improve slowly after correction of 266 
hypercortisolism in parallel with improvements in testosterone levels. In our 267 
study, glucocorticoid equivalent doses did not differ between women with 268 
normal and those with elevated haematological parameters. A previous study 269 
of testosterone replacement in two men with aromatase deficiency has shown 270 
that the action of testosterone on erythropoiesis does not require its 271 
aromatization to oestrogen 32.  272 
 273 
In our study, androgen precursors androstenedione and 17-OHP were weakly 274 
associated with erythropoietic markers compared with testosterone. 275 
Androgenic precursors exert their androgenic effect through conversion to 276 
testosterone and do not directly activate the androgen receptor, which may 277 
explain the weaker relationship with erythropoiesis. Free testosterone may 278 
have a stronger association with erythropoiesis but was not calculated in the 279 
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present study because sex hormone binding globulin (SHBG) was not 280 
measured. We have however adjusted our data for body mass index, which 281 
relates inversely to SHBG levels. It would be of interest to examine the 282 
association of Hb and Hct with dihydrotestosterone, which has tenfold greater 283 
affinity for androgen receptor than testosterone 33. However, 284 
dihydrotestosterone is not routinely measured in the clinical setting and 285 
therefore was not available in the present study. Chronic kidney disease is 286 
also associated with anaemia due to the reduction in renal production of 287 
erythropoietin 34. In the two cohorts presented here there were no subjects 288 
with chronic kidney disease and the relationship between androgens and 289 
markers of erythropoiesis continued to persist after adjusting for creatinine. 290 
 291 
The two cohorts of women could potentially have differences in genotypes 292 
and exposure to lifestyle factors, which could affect the outcomes, but our 293 
results were reproducible in the two cohorts. This is evident by the parallel 294 
regression slopes for the association of testosterone with Hb and Hct in the 295 
two study cohorts. Interestingly, mean Hb and Hct were higher in the UK 296 
cohort than in the US cohort with no differences in androgen levels, body 297 
mass index or glucocorticoid treatment dose between the two cohorts. This 298 
may indicate underlying genetic differences between the two cohorts that 299 
could affect the action of testosterone on erythropoiesis e.g. differences in 300 
androgen receptor CAG repeat lengths. Lifestyle factors such as smoking and 301 
dietary iron intake and menstruation status may be some other factors to 302 
consider, however both cohorts had similar mean age. Compliance with 303 
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glucocorticoid treatment or error in reporting of treatment dose may also 304 
explain this difference. 305 
 306 
Strengths and limitations of the present study: The strengths of the present 307 
study lie in its robust cross-validation study design and adjustments for a 308 
number of major confounding factors. The study is limited by its retrospective 309 
nature and sampling bias might have been introduced as data collection 310 
spanned across approximately ten years. Different assays had been used 311 
during this period, which might have affected the accuracy of the biochemical 312 
data and also the two cohorts have used different assay techniques for 313 
androgens, which limits the comparison between the two cohorts. Another 314 
limitation of the study is wide variation of androgen levels observed in both 315 
cohorts. However, this reflects the previous observations with poor disease 316 
control on current therapeutic regimens 9 and potentially affected by 317 
differences in time of blood sampling. Lifestyle factors such as diet and 318 
smoking history were not available given this was a retrospective study.  319 
 320 
In conclusion, the strong association of adrenal androgens with Hb and Hct in 321 
two cohorts of women with CAH suggests that these markers of 322 
erythropoiesis may be considered as biomarkers of disease control in women 323 
with CAH and in those with polycythaemia or anemia under or over 324 
suppression of adrenal androgens should be considered as a cause. Chronic 325 
over and under-treatment of CAH patients may have an effect on 326 
erythropoiesis, which can also potentially impact physical performance 35.  327 
 328 
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Tables 
 
 
 
 
Table 1. Characteristics of women with congenital adrenal hyperplasia in cohort 1, 
UK (n = 23) and cohort 2, US (n = 53). 
 
 
Cohort 1 
(n = 23) 
Cohort 2 
(n = 53) 
Group difference 
(cohort 1 minus cohort 2) 
 Mean (SD) Mean (SD) Mean (95% CI) P 
 
Age (years) 35.3 (13.9) 30.8 (11.4) 4.4 (-1.6, 10.5) 0.148 
Haemoglobin (g/L) 140.4 (13.3) 134.1 (10.5) 6.3 (0.6, 11.9) 0.031 
Haematocrit (%) 41.7 (04.0) 39.9 (3.1) 1.8 (0.1, 3.5) 0.035 
17-OHP (nmol/L) 98.3 (151.4) 127.1 (150.1) -28.9 (-110.7, 53.0) 0.484 
Androstenedione (nmol/L) 12.4 (13.3) 15.4 (19.6) -3.0 (-12.3, 6.3) 0.519 
Testosterone (nmol/L) 3.2(6.1) 2.7 (5.5) 0.5 (-2.4, 3.4) 0.748 
Height (m) 1.58 (0.08) 1.57 (0.08) 0.00 (-0.03, 0.05) 0.687 
Weight (kg) 86.4 (27.2) 78.2 (29.0) 8.1 (-8.8, 24.4) 0.323 
Body mass index (kg/m2) 34.6 (11.4) 31.7 (12.1) 2.9 (-3.9, 9.7) 0.396 
Serum creatinine (µmol/L) 66.5 (13.1) 73.6 (14.4) -7.1 (-14.3, 0.10) 0.053 
Glucocorticoid treatment 
dose (mg/day) 
28.2 (11.2) 29.4 (13.4) -1.3 (-7.7, 5.1) 0.692 
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Table 2. Partial correlations of haemoglobin and haematocrit with androgens in women from two separate study cohorts. All 
analyses were adjusted for age. Further adjustments were made for glucocorticoid treatment dose, CAH status and serum 
creatinine.  
  
 
Ln 17-OHP Ln Androstenedione Ln Testosterone 
 r P r P r P 
Cohort 1: Adjusted for age 
      
Haemoglobin 0.472 0.056 0.352 0.129 0.712 <0.001 
Haematocrit 0.508 0.037 0.485 0.030 0.705 0.001 
 
Cohort 2: Adjusted for age 
      
Haemoglobin 0.508 0.037 0.372 0.007 0.524 <0.001 
Haematocrit 0.176 0.211 0.298 0.032 0.466 <0.001 
       
Cohort 1: Adjusted for age + CAH status + Ln 
glucocorticoid treatment dose + serum creatinine 
      
Haemoglobin 0.524 0.066 0.555 0.032 0.797 <0.001 
Haematocrit 0.570 0.042 0.724 0.002 0.778 0.001 
 
Cohort 2: Adjusted for age + CAH status + Ln 
glucocorticoid treatment dose + serum creatinine 
      
Haemoglobin 0.301 0.038 0.363 0.011 0.491 <0.001 
Haematocrit 0.168 0.253 0.259 0.075 0.415 0.003 
 
Both cohorts: Adjusted for study group + age 
      
Haemoglobin 0.316 0.008 0.357 0.002 0.545 <0.001 
Haematocrit 0.260 0.031 0.349 0.003 0.497 <0.001 
 
Both cohorts: Adjusted for study group + age + CAH status 
+ Ln glucocorticoid treatment dose + serum creatinine 
      
Haemoglobin 0.294 0.019 0.325 0.008 0.490 <0.001 
Haematocrit 0.225 0.076 0.314 0.010 0.438 <0.001 
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Table 3. Independent t-tests to assess differences in androgens, glucocorticoid treatment dose and anthropometry of CAH women 
with Hb or Hct in the highest tertile compared with those in the lowest tertile (Hb cut-offs at 137 and 147 g/l in cohort 1 and at 130 
and 138 g/l in cohort 2; Hct cut-offs at 41.0 and 43.7% in cohort 1 and at 38.8 and 41.1% in cohort 2). 
 
 Hb: highest tertile 
minus lowest tertile 
Mean difference (95% CI) 
 
P 
 
Hct: highest tertile 
minus lowest tertile 
Mean difference (95% CI) 
 
P 
 
Cohort 1     
Ln 17-OHP (nmol/L) 2.79 (0.94, 4.64) 0.007 2.61 (0.82, 4.39) 0.006 
Ln Androstenedione (nmol/L) 1.83 (0.36, 3.30) 0.018 2.15 (0.72, 3.57) 0.006 
Ln Testosterone (nmol/L) 1.67 (0.20, 3.14) 0.029 1.59 (0.14, 3.03) 0.034 
Ln Glucocorticoid treatment dose (mg/day) 0.04 (-0.43, 0.51) 0.848 0.08 (-0.41, 0.57) 0.781 
Height (m) 0.01 (-0.08, 0.11) 0.755 0.03 (-0.07, 0.13) 0.509 
Body mass index (kg/m2) 1.9 (-16.7, 20.4) 0.824 -3.4 (-15.2, 8.4) 0.522 
     
Cohort 2     
Ln 17-OHP (nmol/L) 1.44 (-0.12, 3.00) 0.069 0.54 (-0.97, 2.05) 0.472 
Ln Androstenedione (nmol/L) 1.44 (0.54, 2.34) 0.003 0.76 (-0.17, 1.70) 0.105 
Ln Testosterone (nmol/L) 1.75 (1.02, 2.48) <0.001 1.27 (0.52, 2.02) 0.002 
Ln Glucocorticoid treatment dose (mg/day) 0.19 (-0.09, 0.48) 0.181 0.25 (0.01, 0.50) 0.043 
Height (m) -0.04 (-0.10, 0.02) 0.193 -0.04 (-0.10, 0.01) 0.140 
Body mass index (kg/m2) 10.1 (3.7, 16.5) 0.003 10.0 (3.7, 16.2) 0.003 
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Figures and Legends 
 
Figure 1. Relationship between haemoglobin and testosterone levels in 
women with CAH (z and solid line indicate cohort 1; U and dashed line 
indicate cohort 2). Regression equations for cohort 1: Haemoglobin = 4.6 
(95%CI: 1.5-7.8) x Ln Testosterone + 141 (95% CI: 137-145) (r2 = 31.5%) and 
for cohort 2: Haemoglobin = 4.4 (95%CI: 2.4-6.5) x Ln Testosterone + 133 
(131-136) (r2 = 27.5%). The slopes of regression did not differ between the 
two cohorts. 
 
 
 
Figure 2. Relationship between haematocrit and testosterone levels in 
women with CAH (z and solid line indicate cohort 1; U and dashed line 
indicate cohort 2). Regression equations for cohort 1: Haematocrit = 1.4 
(95%CI: 0.4-2.4) x Ln Testosterone + 42.0 (95% CI: 40.7-43.4) (r2 = 30.3%) 
and for cohort 2: Haematocrit = 1.2 (95%CI: 0.5-1.8) x Ln Testosterone + 39.7 
(39.0-40.5) (r2 = 21.9%). The slopes of regression did not differ between the 
two cohorts. 
 
 
 
 
